Risk Of Developing Liver Cancer After HCV Treatment

Sunday, September 17, 2017

Coverage OncLive - 2017 International Liver Cancer Association Annual Conference

Conference Website
2017 International Liver Cancer Association Annual Conference
September 15 - 17
Seoul, South Korea

Conference Coverage Available Online At OncLive 
http://www.onclive.com/conference-coverage/ilca-2017

Conference Multimedia
http://www.onclive.com/conference-videos/ilca-2017

Highlights
Study Shows DAAs Are Not Associated With Increased HCC Recurrence Risk
Angelica Welch
Published Online: Monday, Sep 18, 2017
Direct acting antivirals (DAA) are a novel and completely oral hepatitis C therapy that is associated with a high response rate. DAAs are used in most patients being treated for hepatitis C, including those with decompensated cirrhosis.

This type of treatment has now completely replaced interferon-based therapy for patients with hepatitis C, a therapy which was also associated with a decrease in hepatocellular carcinoma (HCC) incidence in 40% to 50% of patients.

Danielle Bucco
Published Online: Friday, Sep 15, 2017
“[At ILCA] we not only cover all of the clinical disciplines involved in the management of liver cancer but the presentations at this meeting include surgical oncology, transplant surgery, hepatology, interventional radiology, pathology, as well as medical oncology,” explained Richard Finn, MD, an associate professor of medicine at David Geffen School of Medicine at University of California, Los Angeles. “One of the most important things the audience will take away from the meeting is the latest data in not only systemic treatments, but also the role of treating hepatitis C in the setting of advanced and early-stage liver cancer. They will go home with some practice-changing observations.”

Danielle Bucco
Published Online: Saturday, Sep 16, 2017
Hepatocyte pERK-positive immunostaining and microvascular invasion were independent prognostic factors of recurrence-free survival (RFS) for patients with hepatocellular carcinoma (HCC) treated with adjuvant sorafenib (Nexavar); however, a predictive biomarker for recurrence was not uncovered, according to an analysis of the phase III STORM study presented at the 11th International Liver Cancer Association Annual Conference

Precision Screening May Improve Surveillance in HCC
Angelica Welch
Published Online: Saturday, Sep 16, 2017
“The highest rates of HCC are in east Asia and Africa, primarily driven by high rates of hepatitis B in those areas. While the incidence of HCC is lower in the United States and Europe, it is gaining a lot of attention because HCC has the largest increasing incidence among all solid tumors over the past 10 years as assessed by SEER,” said Singal, medical director of the Liver Tumor Program at UT Southwestern Medical Center. “Some projections have HCC becoming a top 5 cause of cancer-related death over the next decade in the United States. One of the key ways to curb this increased mortality is to increase rates of early tumor detection and curative treatment.”

Begin here..........

International Liver Cancer Association (ILCA) 
Patient information
What is liver cancer?
Liver cancer is defined by an abnormal and uncontrolled growth of cells within the liver. These altered cells progressively substitute the normal cells, collapsing the normal function of the liver, and invading other organs. These events irremediably lead to the death of the patients affected from this disease. We should distinguish liver cancer from benign tumors, that are also the result of an altered cellular growth, but they lack the invasiveness capacities of the malignant tumors (cancer). Therefore, the prognosis of benign tumors is excellent and in the majority of cases there is no need of treating them.
Continue reading...

No comments:

Post a Comment